Abstract
Purpose: The ability of PET to aid in the diagnosis and management of recurrent and/or disseminated metastatic prostate cancer may be enhanced by the development of novel prognostic imaging probes. Accumulating experimental evidence indicates that overexpression of integrin α2β 1 may correlate with progression in human prostate cancer. In this study, 64Cu-labeled integrin α2β1- targeted PET probes were designed and evaluated for the imaging of prostate cancer. Methods: DGEA peptides conjugated with a bifunctional chelator (BFC) were developed to image integrin α2β1 expression with PET in a subcutaneous PC-3 xenograft model. The microPET images were reconstructed by a two-dimensional ordered subsets expectation maximum algorithm. The average radioactivity accumulation within a tumor or an organ was quantified from the multiple region of interest volumes. Results: The PET tracer demonstrated prominent tumor uptake in the PC-3 xenograft (integrin α2β1-positive). The receptor specificity was confirmed in a blocking experiment. Moreover, the low tracer uptake in a CWR-22 tumor model (negative control) further confirmed the receptor specificity. Conclusion: The sarcophagine-conjugated DGEA peptide allows noninvasive imaging of tumor-associated α2β1 expression, which may be a useful PET probe for evaluating the metastatic potential of prostate cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 1313-1322 |
Number of pages | 10 |
Journal | European Journal of Nuclear Medicine and Molecular Imaging |
Volume | 38 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2011 |
Keywords
- DGEA peptide
- Integrin αβ
- Metastatic biomarker
- Prostate tumor imaging
- microPET imaging
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging